Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc., trading under the ticker symbol VOR, is at the forefront of cell and genome engineering, specifically focusing on hematopoietic stem cells (HSCs). Headquartered in Cambridge, Massachusetts, Vor Bio aims to revolutionize the treatment of hematological cancers, particularly acute myeloid leukemia (AML). The company’s pioneering platform involves engineering hematopoietic stem cells (eHSCs) to generate healthy and functional cells with beneficial modifications. These modifications protect the blood and bone marrow from the adverse effects of antigen-targeted therapies while leaving cancer cells vulnerable.
Key Products and Innovations:
- VOR33 (Trem-cel) - Vor Bio’s lead program, a CRISPR/Cas9 genome-edited allogeneic HSC transplant that lacks the CD33 protein. This product is designed to replace standard transplants for AML patients and potentially other blood cancers.
- VCAR33ALLO - A CD33-directed CAR-T cell therapy derived from healthy transplant donor cells. This approach aims to provide more potent and durable responses in the post-transplant setting without on-target toxicity.
Recent Achievements and Collaborations:
- Secured a non-exclusive worldwide license from Editas Medicine for ex-vivo Cas9 gene-edited HSC therapies.
- Partnership with Janssen for the preclinical development of CD33-deleted allografts and their synergistic effects with Janssen's CD33-targeted immunotherapy candidate.
Clinical Trials and Research:
- VBP101 Clinical Trial - Ongoing Phase 1/2a study of trem-cel in AML patients, showing promising engraftment results and hematologic protection.
- VCAR33ALLO Clinical Trial (VBP301) - A Phase 1/2 study involving CAR-T cell therapy derived from healthy transplant donors, showing initial successful dosing and manufacturing capabilities.
Financial Updates: In its latest quarterly report, Vor Bio announced positive financial outcomes, including an extended cash runway into the second half of 2025. The company is focused on executing its clinical trials and expanding its platform to include additional innovative therapies.
Future Outlook: Vor Bio is set to present at major scientific conferences, including the American Society of Hematology (ASH) Annual Meeting, where it will share significant preclinical and clinical data. The company is also looking forward to additional data releases from its clinical trials by year-end, which could further validate their treatment system for AML.
For more updates, visit www.vorbio.com.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in several upcoming investor conferences. Notable events include the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, and the Mizuho Oncology Therapeutics Summit on March 13, 2023, in Miami, FL. Vor Bio will also present at the Oppenheimer 33rd Annual Virtual Healthcare Conference on the same day and will attend the Barclays Global Healthcare Conference on March 15, 2023. Investors can access a live webcast and archived replays of these presentations through their website.
Vor Bio (Nasdaq: VOR) has presented promising clinical data from its VBP101 study on trem-cel, a genome-edited therapy targeting acute myeloid leukemia (AML). The therapy demonstrated robust engraftment in the first patient five months post-transplant, maintaining hematopoiesis through three cycles of Mylotarg, with no significant adverse effects. The second patient also achieved successful neutrophil engraftment and platelet recovery. Data showed Mylotarg's potential to protect against hematological toxicity and enrich CD33-negative donor cells. Vor Bio plans to escalate Mylotarg doses and submit an IND for VCAR33ALLO, a new CAR-T therapy, in H1 2023.
Vor Bio (Nasdaq: VOR) announced that clinical data from the initial patient treated in its VBP101 study has been accepted for presentation at the 2023 Tandem Meetings from February 15-19 in Orlando, Florida. This Phase 1/2a trial is focused on trem-cel (formerly VOR33) for patients with acute myeloid leukemia (AML). The late-breaking poster presentation, titled "Initial First-in-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT)," will showcase important findings including tolerability of Gemtuzumab Ozogamicin without cytopenias.
Vor Biopharma (Nasdaq: VOR) will participate in B. Riley Securities’ 3rd Annual Oncology Conference, held virtually on January 18, 2023, at 12:00 PM ET. The event aims to showcase advancements in oncology and will include a fireside chat format. A live webcast of the presentation will be accessible on the company's website, with an archived replay available afterward. Vor Biopharma focuses on transforming the standard of care for blood cancer patients through innovative genome engineering of hematopoietic stem cells.
Vor Bio (Nasdaq: VOR) has announced a dual fundraising initiative, pricing an underwritten offering and a private placement, aiming for combined gross proceeds of approximately $115.8 million. The underwritten offering includes 15,302,267 shares at $4.30 per share, expected to yield about $65.8 million, set to close around December 9, 2022. Concurrently, 11,627,907 shares will be sold privately to RA Capital for an additional $50 million. Proceeds will target clinical development and general corporate needs.
Vor Bio has announced promising initial clinical data from its Phase 1/2a trial of trem-cel (formerly VOR33) for acute myeloid leukemia (AML). The first patient's results indicate successful engraftment and maintenance of blood counts after treatment with Mylotarg. A total of 7.6 x106 CD34+ cells/kg were infused, achieving 100% donor chimerism and robust hematopoietic reconstitution. No adverse events related to Mylotarg were noted, highlighting the treatment's tolerability. A conference call discussing these developments is scheduled for December 7, 2022.
Vor Bio (Nasdaq: VOR), a clinical-stage company focusing on cell and genome engineering, will participate in several investor conferences. The Piper Sandler 34th Annual Healthcare Conference is scheduled for November 29, 2022, at 9:30 am ET in New York. A fireside chat at the 5th Annual Evercore ISI HealthCONx Virtual Conference will occur on December 1 at 3:05 pm ET, followed by another fireside chat at The JMP Securities Hematology and Oncology Virtual Summit on December 6 at 1:20 pm ET. Webcasts of these events will be available on their website.
Vor Bio reported financial results for Q3 2022, showing a cash position of $136.1 million, projected to fund operations until Q1 2024. R&D expenses increased to $16.9 million, driven by clinical trials and facility expansions. The net loss was $23.8 million. In-house clinical manufacturing is now operational, supporting the IND submission for VCAR33 in H1 2023. The company plans to present initial clinical data for VOR33 by the end of 2022 and has received ATMP status from EMA for VOR33 and VCAR33.
Vor Bio (Nasdaq: VOR) has announced its participation in several upcoming investor conferences. Key events include:
- Credit Suisse 31st Annual Healthcare Conference: Virtual presentation on November 8, 2022.
- Stifel 2022 Healthcare Conference: Fireside chat on November 16, 2022, at 10:20 am EST in New York, NY.
- Jefferies London Healthcare Conference: Fireside chat on November 17, 2022, at 3:15 pm GMT in London, UK.
Webcasts of these events will be available on Vor Bio's investor section.
Vor Bio (Nasdaq: VOR) has appointed Dr. Eyal C. Attar as Chief Medical Officer, bringing over 20 years of clinical experience, particularly in hematologic malignancies. The company anticipates important clinical trial data for VOR33 later this year, alongside an IND submission for VCAR33ALLO planned for early next year. Dr. Attar's expertise in AML and prior roles at Aprea Therapeutics and Agios Pharmaceuticals are expected to enhance Vor Bio's clinical development capabilities. An inducement equity award of 364,000 stock options was granted to Dr. Attar as part of his appointment.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
What is Vor Biopharma Inc. known for?
What are the main products of Vor Biopharma Inc.?
Where is Vor Biopharma Inc. located?
What recent achievements has Vor Biopharma Inc. made?
What clinical trials are currently being conducted by Vor Biopharma Inc.?
What is the potential impact of Vor Biopharma Inc.'s platform?
How can I stay updated on Vor Biopharma Inc.'s progress?
What financial updates were provided by Vor Biopharma Inc. recently?
What upcoming milestones is Vor Biopharma Inc. expecting?
What collaborations has Vor Biopharma Inc. entered into?
